Destiny Pharma’s microbiome project for Clostridioides difficile infection
Neil Clark, CEO of Destiny Pharma (AIM:DEST) spoke with Amy Brown at Evaluate Vantage about Destiny’s microbiome project for Clostridioides difficile infection which is in development and differentiates them from other players. “We are coming in as a first-line therapy, and looking at lower pricing” than those going for the high-recurrence end of the market, he says.
Read full Evaluate Vantage article here